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Angiotensin-converting enzyme (ACE) inhibitors 
(ACEI) were developed from a serendipitous discovery 
that a Brazilian snake venom contained a bradykinin- 
potentiating factor with vasodilating properties (Fer- 
reira, '65). The physiological significance of this was 
established by demonstrating inhibition of ACE by the 
peptide mixture from the snake venom (Bakhle, '68). 
The first clinically usable ACEI, captopril, was synthe- 
sized in 1975 (Cushman and Ondetti, '91). In the 
United States, captopril (Capoten") was approved for 
clinical use in 1981, followed by enalapril (Vasotec@) in 
1985, lisinopril (Prinivil@, Zestriln) in 1987, benazepril 
(Lotensin@), fosinopril (MonopriP), and ramipril (Al- 
tacea) in 1991, and quinapril (Accupril@) in 1992. 
Other ACEIs discussed in the literature but not cur- 
rently marketed in the United States include abu- 
tapril, alacepril, ceronapril, cilazepril, delapril, 
idrapril, imidapril, moexipril, pentopril, perindopril, 
rentiapril, spirapril, temocapril, trandolapril, zabicip- 
ril, and zofenapril. 
Two of the currently available ACEIs, captopril and 
lisinopril, are in the active form; the others are proac- 
tive drugs that are deesterified in the liver to the active 
form (designated by the suffix -prat) and were devel- 
oped to enhance absorption or prolong activity or  both. 
Captopril binds the enzyme by means of a sulfhydryl 
group, fosinopril by a phosphodyl group, and the others 
by a carboxyl (Materson and Preston, '94). ACEIs are 
mainly excreted through the kidney, although up to 
50% of ramipril and fosinopril is excreted in the feces 
(Williams, '88; manufacturers' literature). 
Placental passage of the various ACEIs appears to be 
both species and drug dependent. In common labora- 
tory animals there may be little passage of some ACEIs 
through the placenta (Endo et  al., '92). However, in 
humans i t  is established from measurements in ex- 
posed newborns that enalapril, captopril, and lisinopril 
do cross the placenta in pharmacologically significant 
amounts, and i t  is assumed that the other available 
ACEIs also cross the human placenta (Schubiger et al., 
'88; Pryde et al., '93). Once in the fetus, it may be pre- 
sumed that an  ACEI will be renally excreted (provided 
there is urine production) largely as the active drug, 
which may then be swallowed and recirculated. What 
import such drug recirculation might have on fetal 
physiology has not been assessed. 
USE OF ACEIs 
Since their introduction, ACEIs have come to be re- 
garded as a major advance in the treatment of hyper- 
tension (Thurston, '92; Rodicio and Ruilope, '93; Mat- 
erson and Preston, '94). It has been observed that most 
types of hypertension respond favorably to ACEI ther- 
apy, with or without the addition of diuretics (Sassano 
et  al., '87; Garay et al., '94). Antihypertensives such as 
beta-adrenergic receptor blockers and diuretics tend to 
increase peripheral resistance and have side effects on 
the metabolism of electrolytes, glucose, and lipids. In 
contrast, ACEIs decrease vascular resistance, improve 
glucose handling, control left ventricular mass, and of- 
fer a degree of myocardial protection (Williams, '88; 
Gavras, '88; Materson and Preston, '94). In the absence 
of heart failure, ACEIs produce little change in heart 
rate, cardiac output, or pulmonary wedge pressure in 
normal or  hypertensive people (Vidt et al., '82; Todd 
and Heel, '86; Gomez et al., '87). They have also been 
found to contribute to an improved quality of life for 
the hypertensive patient, particularly when compared 
to beta-blockers (Materson and Preston, '94). 
A use for ACEIs that has excited considerable inter- 
est stems from the demonstration that they impede the 
progression of nephropathy associated with diabetes 
mellitus, both type 1 and type 2 (Ravid et al., '93; 
Bakris, '93; Viberti et al., '94). The ACEIs reduce mi- 
croalbuminuria, preserve renal function, and increase 
insulin sensitivity; these effects are believed to be in- 
dependent of the antihypertensive action of these drugs 
(Ravid et al., '93). 
Guthrie ('93) reported that prescriptions for ACEIs 
increased nearly 250% between 1986 and 1990, testi- 
fying to their popularity in clinical use, and many ar- 
ticles have appeared extolling their use as first line 
agents in the treatment of hypertension. The use of 
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ACEIs for myocardial protection poses little concern to 
the teratologist, since the vast majority of such use will 
be in  patients beyond the childbearing years. However, 
their use for mild or essential hypertension, and in 
such conditions as the autoimmune diseases and dia- 
betes mellitus, could expose a considerable number of 
women in the childbearing years, not a few of whom 
will be pregnant. The use of ACEIs for the manage- 
ment of pregnancy-induced hypertension, by defini- 
tion, creates a certain and identifiable fetal exposure. 
The actual number of pregnancies exposed to ACEIs 
cannot be determined from available data. Piper et al. 
('92) reported that of 106,813 Tennessee Medicaid pa- 
tients who delivered a live or stillborn infant during 
1983-1988, 19 were exposed to an ACEI. Given the 
expansion of use of these agents to the current time, it 
would be reasonable to expect that the number of fetal 
exposures will increase. 
ADVERSE EFFECTS 
In the enthusiasm to employ ACEIs as first line 
agents for treatment of hypertension and t o  retard de- 
velopment of diabetic nephropathy, their safety some- 
times seems to be overstated. As wonderful as they 
seem, ACEIs are not without adverse effects. As de- 
scribed below, because they suppress aldosterone secre- 
tion, they are liable to produce hyperkalemia, particu- 
larly in the face of sodium restriction, heart failure, 
diabetes, and coadministration of potassium-sparing 
diuretics and nonsteroidal anti-inflammatory drugs 
(Williams, '88; Schlueter et al., '94). Their use in cer- 
tain circumstances, such as bilateral renal artery ste- 
nosis, can contribute to, not ameliorate, renal dysfunc- 
tion (Hricik et al., '83; Cooke and Debesse, '94). In some 
cases the dysfunction may be reversible (Wood et al., 
'91) and in others irreversible (Devoy et al., '92). Per- 
haps the most common side effect of the ACEIs is an 
irritating cough, which ironically has generated more 
literature than has the possibility of fetal damage. 
As early as 1980, there were reports of fetal wastage 
in ACEI-exposed experimental animals (Broughton- 
Pipkin et al., '80, '82; Ferris and Weir, '82). In 1981, the 
first adverse outcome in a human pregnancy was re- 
ported (Duminy and Burger, '81). This was followed in 
short order by other cases implicating both captopril 
and enalapril as  potential fetotoxins (Guignard, '82; 
Boutroy et al., '84; Caraman et al., '84; Fiocchi et al., 
'84; Rothberg and Lorenz, '84). Warnings about the use 
of ACEIs in human pregnancy appeared in the litera- 
ture as early as 1985 (Lindheimer and Katz, '85). On 
the other hand, some recent reviews of the ACEIs make 
no mention of the possibility of adverse fetal effects 
(Materson and Preston, '94; Pinkney and Yudkin, '94). 
Pryde et  al. ('93) recently proposed the designation 
"ACE inhibitor fetopathy," summarized 29 affected 
cases from the literature, and added 3 more. Two more 
cases have been reported since the review by Pryde et 
al. (Piper et al., '92'; Thorpe-Beeston et al., '93), and I 
have received at least partial reports of five others from 
medical colleagues and attorneys. It appears that the 
bulk of ACEI fetopathy cases have ensued after enal- 
april exposure, but cases associated with captopril and 
lisinopril are recorded (Hanssens et  al., '91; Pryde et  
al., '93). As pointed out by Brent and Beckman ('gl), 
there is no reason to assume that the other ACEIs are 
incapable of producing the same result. Similarly, 
many of the cases have involved coexposure to other 
antihypertensive agents, and while combination ther- 
apy may pose more risk to the fetus, monotherapy with 
an  ACEI has produced the full-blown fetopathy. 
The most commonly reported adverse effect of ACEI 
exposure of the fetus is that of second to third trimester 
onset of oligohydramnios and growth restriction, fol- 
lowed by delivery of an infant whose neonatal course is 
complicated by prolonged and often profound hypoten- 
sion and anuria (Rosa et a]., '89). The presentation may 
also include the oligohydramnios deformation se- 
quence and its lethal component, pulmonary hypopla- 
sia (Guignard et al., '81; Mehta and Modi, '89; Cunniff 
et al., '90; Pryde et al., '93). Although studies of the 
histology of the kidneys in ACEI-exposed fetuses and 
infants are few in number, they are consistent in their 
demonstration of renal tubular dysgenesis (Knott et 
al., '89; Cunniff et al., '90; Pryde et al., '93). Delayed 
development of the calvaria has been noted in enough 
cases to consider it a part of the syndrome. Postnatal 
persistence of a patent ductus arteriosus (PDA) has 
also been suggested to be part of the syndrome, but it is 
hard to determine if this finding is an  effect of ACEI 
exposure. 
The true rates of adverse fetal effects from ACEI use 
in human pregnancy cannot be determined from avail- 
able information. Certainly, a number of exposed preg- 
nancies have resulted in no measurable adverse effect 
(Ducret et al., '85; Kreft-Jais et al., '88; Piper e t  al., 
'92). In the largest published series there were 31 preg- 
nancies exposed either to captopril (n = 22) or enala- 
pril (n = 9) (Kreft-Jais et al., '88). The reported adverse 
outcomes included nine cases of intrauterine growth 
restriction, three intrauterine deaths, and two infants 
with PDA, of which one ultimately required ligation. 
The 22 other cases in this report were presumably un- 
affected. 
The adverse developmental effects of ACEIs are pur- 
posely designated ACEI fetopathy because as yet there 
is no convincing evidence that they cause harm in the 
first trimester of human gestation or its equivalent in 
laboratory animals. Studies with captopril and enala- 
pril in rats failed t o  show malformations resulting from 
lone  case described by Piper et al. ('921, with microcephaly and 
encephalocele, was classified as an example of hypocalvaria: I believe 
this infant's problems were probably unrelated to ACEI exposure. 
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high doses (Fujii et al., '85; Fujii and Nakatsuka, '85; 
Robertson et al., '86; Al-Shabanah et al., '91; Al-Harbi 
et al., '92), although at the highest doses tested, fetal 
growth restriction, delayed ossification, and resorp- 
tions were noted in conjunction with evidence of ma- 
ternal toxicity. In humans, the case reported by 
Thorpe-Beeston et al. ('93) was found to have renal 
cystic dysplasia, a disorder distinct from the renal tu- 
bular dysgenesis found in other cases, but still likely to 
be a fetal rather than an embryonic effect. In the case 
reported by Duminy and Burger ('81) there was a ter- 
minal transverse deficiency of a limb, again likely to be 
of fetal origin. The second case mentioned by Piper et 
al. ('92) was remarkable for microcephaly and enceph- 
alocele, the latter almost certainly a problem of first 
trimester origin, and I am aware of an enalapril expo- 
sure-associated case of anencephaly. These few dispar- 
ate anomalies associated with ACEI exposure do not 
constitute sufficient evidence of true teratogenicity, al- 
though admittedly there is insufficient evidence to be 
confident of safety in the first trimester. Currently, the 
recommendation is to offer reassurance of unlikely first 
trimester effects, but to avoid second and third trimes- 
ter exposure, unless absolutely necessary for the moth- 
er's well being. 
REVIEW OF RENIN-ANGIOTENSIN 
SYSTEM (RAS) 
Angiotensin I is a decapeptide formed from the ac- 
tion of renin on its precursor, angiotensinogen (Fig. 1). 
Angiotensin I has no known biological action in hu- 
mans but is rapidly converted to the biologically active 
octapeptide, angiotensin 11. This conversion is effected 
by ACE, a zinc metalloprotease that catalyzes the hy- 
drolysis of carboxy-terminal dipeptides from oligopep- 
tide substrates. The principal substrates are angioten- 
sin I and the nonapeptide, bradykinin, but other 
substrates are affected as well (Ehlers and Riordan, 
'89). Angiotensin I1 is a potent vasoconstrictor, stimu- 
lates aldosterone secretion from the adrenal cortex, 
and suppresses renin release by increasing sodium re- 
tention, whereby it closes a negative-feedback loop. A 
parallel system involves the formation of bradykinin 
and its inactivation by kininase TI (which is identical 
with ACE). Angiotensin I1 raises blood pressure, and 
bradykinin, if not inactivated by the enzyme, lowers 
blood pressure. 
ACE has two catalytic sites, one near the carboxyl 
terminus and one near the amino acid terminus. These 
sites may have specific substrates, but angiotensin I 
and bradykinin appear to be catalyzed equally at  both 
sites (Johnston et al., '93). The ACE gene is develop- 
mentally regulated in a tissue-specific manner and 
plays a role in the regulation of renal function and 
growth (Yosipiv et al., '94). The ACE gene exhibits 
polymorphism, marked by the insertion or deletion of a 
250 bp fragment in intron 16 of the gene (Rigat et al., 
Kininogen Angiotensinogen 1 C--, Renin 1 Kaliikrein ---t 
Arachidonic, Bradykinin\/ Angiotensin I 
Acid 
Kininase II 1 Converting Enzyme I ECF Expaniion 
Na+ Retention 
? Prostaglandin I 1 L Aidoeterone J 
Fig. 1. Schematic representation of the renin-angiotensin-bradyki- 
nin system. ECF = extracellular fluid. 
'90). Homozygotes for the deletion (DD) show the high- 
est serum levels of ACE activity, while homozygotes for 
the insertion (11) have the lowest levels. The prevalence 
of the gene types varies in different populations (Lee, 
,941, and it has been reported that the deletion geno- 
type is less prevalent in diabetic patients with ne- 
phropathy than in those without nephropathy (Marre 
et al., '94). Angiotensin I1 receptors similarly have two 
types: type 1 (AT,) is found in a wide variety of tissues 
in the adult and seems to mediate all the known effects 
on angiotensin I1 related to the RAS. This type of re- 
ceptor has two subtypes, ATlA and ATlB, which are 
said to show few pharmacological differences and may 
function as growth factors. While the type 2 (AT,) re- 
ceptor is the predominant type found in the gestational 
day (GD) 19 rat fetus, fetal adrenal cortex and renal 
glomeruli express both AT,, and AT,, mRNAs (Grone 
et al., '92; Shanmugam et al., '94). Their roles in fetal 
development are being investigated. What effect such 
genetic diversity, in mother or fetus, may have on the 
Occurrence of adverse fetal effects from ACEI exposure 
is unknown at this time, but should be explored. 
The RAS becomes crucially important under condi- 
tions of low renal perfusion pressure (Hall et al., '77; 
Blythe, '83). In these conditions, which pertain to the 
fetus, angiotensin 11-mediated efferent arteriolar resis- 
tance is essential to the maintenance of glomerular 
filtration (GFR) and production of urine (Rudolph et 
al., '71; Giugnard, '82). Activation of bradykinin by 
suppression of angiotensin I1 can compromise GFR by 
virtue of bradykinin's vasodilatory effect on the effer- 
ent arteriole (Kon et al., '93). In the adult, ACEIs in- 
crease renal blood flow. Usually this occurs without 
modifying the GFR because vasodilation of efferent ar- 
terioles exceeds that of the afferent arterioles (Wil- 
liams, '88). In cases of renal artery stenosis, bilateral or 
unilateral in a solitary kidney, there is an inability to 
increase renal blood flow sufficiently to compensate for 
the efferent arteriolar dilation and maintain glomeru- 
lar perfusion pressure (Hricik et al., '83). 
In pregnancy-induced hypertension mean arterial 
blood pressure is correlated with serum ACE activity 
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(Li et al., '92) and is characterized by enhanced an- 
giotensin I1 sensitivity due to an increase in angioten- 
sin I1 receptor number (Graves et al., '92). However, 
the RAS is known to be both a circulating and a tissue 
hormonal system, and, of the two, tissue systems may 
be the more important (Ehlers and Riordan, '89; 
Johnston et al., '92). ACE is widely distributed in the 
body; it has been found in soluble form in body fluids 
and in membrane-bound form in arterial endothelial 
cells within and outside the pulmonary circulation, in 
epithelial cells with brush borders (placenta, kidney, 
intestine, and choroid plexus), in neuroepithelial cells, 
and in the male genital tract (testis, prostate, and ep- 
ididymis) (Erdos and Skidgel, '87). Evidence is emerg- 
ing that plasma ACE inhibition and hemodynamic re- 
sponses are separable (Lees et al., '92). Prolonged 
treatment with an ACEI results in an increase of 
plasma ACE but a decrease of ACE in the renal cortex 
and renal brush border (Michel et al., '93). This indi- 
cates that plasma and epithelial ACE are subject to 
local regulatory factors. The renal proximal convoluted 
tubule contains angiotensinogen, ACE, and angioten- 
sin I1 receptors (Moe et al., '93; Jackson et al., '91). Moe 
et al. ('93) found that renin could not be found in tu- 
bules from normal rats, but after enalapril administra- 
tion, renin was found. This was interpreted as evidence 
of a tissue RAS that could generate angiotensin I1 to 
locally regulate sodium absorption. 
It has been suggested that in part the effects of 
ACEIs are due to a locally acting, prostaglandin-depen- 
dent component to their hypotensive action. Linz et al., 
('93) reported that when bradykinin degradation was 
inhibited by ramipril, formation of the endothelial au- 
tacoids, nitric oxide and prostacyclin, was enhanced, 
which they felt contributed to the beneficial effects of 
the drug. Similar conclusions were reached by others 
(Vanhoutte et al., '93; Busse et al., '93). On the other 
hand, Gerber et al. ('93) found that while indomethacin 
reduced the urinary excretion of prostacyclin metabo- 
lite by more than 50%, it had no effect on the hypoten- 
sive effect of captopril or enalapril. They concluded 
that neither ACEI had a significant prostacyclin-de- 
pendent component to its hypotensive action, and Gan- 
sevoort et al. ('94) concluded that the antiproteinuric 
and renal hemodynamic effects of ACEIs were primar- 
ily due to interference in the RAS, rather than the 
bradykinin system. For now, the relation of the effects 
of the ACEIs to bradykinin degradation and prosta- 
glandin production is not resolved. These two hor- 
mones may be acting at the tissue level without corre- 
lated change in blood or excretion levels. Involvement 
of the prostaglandin system in ACEI fetopathy seems 
possible, particularly given the number of reported in- 
stances of renal tubular dysgenesis (RTD)/fetal-neona- 
tal anuria associated with nonsteroidal anti-inflamma- 
tory agent exposure (vide infra). 
Tissue kinin generation and degradation are coordi- 
nately regulated during intrauterine development, 
while circulating angiotensin I1 and ACE activity 
change reciprocally (Yosipiv et al., '94). It appears that 
kinins and angiotensin I1 influence the development of 
ACE. It has been established that the RAS is active in 
fetal life, when it plays an essential role in maintain- 
ing GFR under conditions of low renal perfusion pres- 
sure (Jelinek et al., '86). At least in the lamb, it seems 
that the RAS i s  more active in the fetus than in the 
neonate (Binder and Anderson, '92). 
Angiotensin I1 may also act on the growth of its tar- 
get tissues. Some cells, such as those of the adrenal 
cortex, show induction of cell division by angiotensin 
11. The mechanism by which angiotensin I1 induces hy- 
perplasia of its target tissues is largely unknown but 
may be from a direct action on proto-oncogene synthe- 
sis or an indirect action on growth factor secretion 
(Clauser et al., '92). As previously noted, the subtypes 
of angiotensin I1 receptors may function differentially 
as growth factors (Shanmugam et al., '94). 
ANIMAL STUDIES 
Classical studies of the ACEIs given during the pe- 
riod of organogenesis to rats and rabbits have failed to 
demonstrate an increased incidence of malformation. 
To emphasize a point made previously, lack of terato- 
genicity does not mean lack of fetotoxicity. The admin- 
istration of ACEIs to commonly used laboratory ani- 
mals, in late gestation and during lactation, in doses 
comparable to those used in human therapy, has been 
associated with significant fetal and neonatal wastage. 
These are fetotoxic not teratogenic effects. However, as 
described below, none of these species is an especially 
good model for the ACEI fetopathy seen in humans. So 
far, no exploration of maternal and fetal ACEI effects 
and physiology seems to have been done in nonhuman 
primates which might be much better models of the 
effects seen in humans; the development of such models 
should be encouraged. 
Rabbit model 
The adult rabbit is particularly sensitive to ACEIs, 
showing a greater antihypertensive effect than does 
the rat or dog. As measured by blockade of the acute 
pressor response to exogenous angiotensin 1, enalapri- 
lat and captopril are of equal potency in pregnant and 
nonpregnant rabbits (Manson, personal communica- 
tion). The administration of 2.5-5.0 mgikgiday of cap- 
topril to pregnant rabbits yielded pregnancy loss rates 
ranging from 37 to 92% (Broughton-Pipken et al., '80, 
'82; Ferris and Weir, '82). The ED50 values for block- 
ade of the pressor response to angiotensin I by enala- 
prilat in the rabbit, rat, and dog were 2.8, 5.1, and 6.4 
mgikg, respectively. Comparable ED50 values for cap- 
topril in these 3 species were 2.88, 26.1, and 80 mgikg, 
respectively (Manson, personal communication). The 
basis for this sensitivity in rabbits is not known. 
The late gestation rabbit fetus has been shown to be 
highly sensitive to the fetotoxic effects of ACEIs. When 
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administered in the human therapeutic range, ACEIs 
produce fetal deaths in mid to late gestation, with a 
peak effect on GD 26 (Keith et al., '82; Broughton-Pip- 
kin et al., '82; Minsker et al., '90). Maternal toxicity, as 
evidenced by elevation of blood urea nitrogen (BUN) 
and creatinine, and occasionally maternal death, oc- 
curs at the same treatment levels as  those causing fetal 
deaths. Fetal deaths observed in rabbits with ACEI 
treatment may be the result of decreased placental per- 
fusion commensurate with systemic hypotension in the 
mother, rather than of a direct effect on fetal renal 
perfusion (Ferris and Weir, '82; Binder et al., '89; 
Binder and Faber, '92). Captopril studies in the rabbit 
showed no effect on amniotic fluid volume, amniotic 
fluid electrolyte composition, or fetal plasma urea ni- 
trogen, creatinine, or  calcium levels (Manson, personal 
communication), When plasma volume was expanded 
by saline supplementation, maternal toxicity was re- 
duced but fetal deaths continued, particularly a t  
higher dosage levels (enalapril30 mg/kg/day) (Minsker 
et al., '90). 
Rat model 
The maturation of the RAS in the fetal and neonatal 
rat kidney has been thoroughly studied (Ice et al., '88). 
Expression of the gene for the angiotensin I1 receptor 
was not detected in the liver of newborn rats, but in 
their kidneys gene expression was 2.5 times higher 
than in the adult (Iwai et al., '91). Decreasing concen- 
trations of plasma renin from fetal, to newborn, to neo- 
natal rats are consistent with increased activity of the 
RAS in immature animals (Jelinek et al., '86). Renin 
was first detected by immunostaining in the kidney on 
GD 19, when i t  was located in the arcuate and inter- 
lobular arteries. On GD 20, renin also appeared in the 
afferent arteriole. With advancing age, detectable re- 
nin disappeared progressively from the arcuate and in- 
terlobular arteries until i t  was restricted primarily to 
the afferent arteriole in the 20-day-old postnatal pup 
and finally only to  the juxtaglomerular apparatus in 
the adult kidney. A similar but more rapid progression 
of maturation has been observed in the mouse (re- 
viewed by Ice et al., '88). Studies of the synthesis of 
renin mRNA in the rat have shown the same pattern 
and timing (Gomez et al., '89). 
The relevance of these findings to reproductive and 
developmental toxicity studies of ACEIs in rats is that 
the RAS develops late in gestation, beyond the time 
when treatment typically is administered in a segment 
I1 rat developmental toxicity study (GD 6-17). Not sur- 
prisingly, then, results from these studies have uni- 
formly failed to reveal any adverse effects on fetuses, 
with the exception of decrease in fetal body weight and 
ossification a t  treatment levels that also produce evi- 
dence of maternal body weight decreases. 
Interestingly, results from female fertility and late 
gestationilactation studies, in which ACEI exposure oc- 
curred during the critical period of fetal renin synthe- 
sis (GD 19), have demonstrated adverse effects on ne- 
onates (Robertson et al., '86). At high treatment levels 
(approximately 30-300 mgikgiday for enalapril and 
lisinopril), pup deaths occurred during lactation. At 
lower treatment levels (10 mg/kg/day), decreased pre- 
and postweaning body weight gain was observed. Sim- 
ilar findings have been obtained with other ACEIs, 
quinapril (Dostal et al., '91) and rentiapril (Cozens et 
al., '87). 
Late gestationilactation studies, with treatment 
from GD 15 to the end of lactation, would seem to pro- 
vide the most sensitive appraisal of ACEI effects on rat 
pups. Kidneys from weanlings whose mothers received 
quinapril during late gestation (GD 15 on) and/or lac- 
tation had juxtaglomerular cell hypertrophy (Dostal et 
al., '91; Graziano et al., '93), although the latter au- 
thors reported they observed no morphological changes 
in the renal tubules and no adverse effects on renal 
function. Early postnatal treatment with the ACEIs 
enalapril and captopril, and the angiotensin receptor-1 
blocker losartan, but not the angiotensin receptor-2 
blocker PD-123319, in the spontaneously hypertensive 
rat (SHR) and the normotensive strains WKY and WR 
produced persistent, irreversible histopathological re- 
nal changes in adult life, long after the treatment had 
stopped. These abnormalities were associated with im- 
paired urine concentrating ability (Friberg et al., '94). 
This should be looked a t  for other ACEIs. For the most 
part, histopathology from such kidneys has either not 
been done or not been reported in the literature. 
All in all, i t  does not appear that the rat is a suitable 
model for predicting or understanding ACEI fetopathy 
in humans. The RAS develops much later in gestation 
in rats than in humans, and in rats toxicity is mani- 
fested in neonates and weanlings, while in humans the 
major manifestations are seen prenatally and at birth. 
Also, from the available data, it appears that the rat  
placenta is an effective barrier to ACEI penetration 
into the fetal compartment, although more data are 
needed on this point. 
Sheep model 
The chronically catheterized sheep serves as  an ex- 
cellent model to study the cardiovascular and renal 
changes in the maternal and fetal compartments oc- 
curring during pregnancy (Magness e t  al., '85; Hill and 
Lumbers, '88). When captopril, which crosses the sheep 
placenta and blocks the fetal RAS, was administered in 
late pregnancy (GD 119-133, term = 147) a t  2.8-3.5 
mgikg IV to the ewe following exogenously adminis- 
tered angiotensin I, maternal blood pressure was tran- 
siently reduced and returned to normal within 2 hr. 
Fetal blood pressure remained reduced for up to 2 days, 
and 7 of 8 lambs were stillborn (Broughton-Pipkin et 
al., '82). 
In a similar model, fetal renal function was studied 
in sheep given captopril (GD 123-133) a t  an  infusion 
rate of 15 mg IV for 4 days, followed by an intrafetal 
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infusion of angiotensin I1 (6 kg/kg/hr). Fetal GFR de- 
creased from an initial 4.2 to 2.7 ml/min after maternal 
captopril administration, and 3 days later it was 1.5 
ml/min. When the fetuses were given angiotensin I1 
intravenously, fetal GFR returned to a mean of 3.4 
ml/min. It was concluded that a small fall in fetal ar- 
terial pressure partly contributed to the fall in fetal 
GFR but efferent arteriolar tone fell also so that the 
filtration pressure fell further. Thus maintenance of 
fetal renal function depends on the integrity of the fetal 
RAS (Lumbers et al., '92, '93). 
Enalapril has also been studied in the sheep model 
(Broughton-Pipkin and Wallace, '86). Enalapril was 
given at a dose of 1 or 2 mglkg IV at a median gesta- 
tional age of 128 days. A pressor response to exogenous 
angiotensin I (5 pg IV) was first established in the 
maternal compartment: maternally administered an- 
giotensin I had no effect on fetal blood pressure. Fol- 
lowing the administration of enalapril, maternal blood 
pressure was decreased for 30 min, but there was no 
effect on fetal heart rate, plasma renin, or ACE activ- 
ity. At the high dose of enalapril tested, there was a 
transient fall in fetal blood pressure, considered to be 
due to changes in uteroplacental blood flow rather 
than to a direct effect of the drug on the fetus. Trace 
amounts of enalapril were found in fetal plasma, and 
levels of its active metabolite, enalaprilat, were unde- 
tectable in three of four fetuses. One unexplained fetal 
death occurred in the 2 mglkg enalapril group. It was 
concluded that there was minimal transfer of the drug 
into the fetal compartment. Thus, the sheep model may 
not be specifically informative about the effects of ex- 
posure on the human fetus for all ACEIs, for enalapril 
does cross the human placenta and evidently acts di- 
rectly on the fetus. 
FEATURES OF ACEI FETOPATHY 
RTD 
RTD is characterized by dilation of Bowman's spaces 
and tubules, diminished to absent differentiation of 
proximal convoluted tubules, and increased cortical 
and medullary mesenchyme (and later fibrosis) (Fig. 
2). The histological changes in the kidney strongly sug- 
gest ischemic injury, with the added component of de- 
ficient tubular differentiation most easily confirmed by 
failure of periodic acid Schiff stain to stain the brush 
border of proximal convoluted tubules. It has been my 
experience that, unless specifically looked for, the his- 
topathological changes of RTD in the fetalheonatal 
kidney can be and have been missed. RTD was fully 
described in four cases of ACEI fetopathy (Cunniff et 
al., '90; Pryde et al., '93) and has been observed in a 
number of unreported cases. 
To examine the specificity of this set of histopatho- 
logical findings for ACEI exposure, Martin et  al. ('92) 
examined the kidneys of nine fetuses whose mothers 
were chronically hypertensive. Three of these mothers 
used antihypertensive agents throughout pregnancy, 
including one who used an ACEI. The tubular morphol- 
ogy of these kidneys was compared with the renal tu- 
bules of 20 normal controls, 13 fetuses with various 
multiple malformation syndromes, and 6 cases of the 
twin-twin transfusion syndrome. Features of RTD were 
identified in two cases of twin-twin transfusion syn- 
drome, the ACEI-exposed case, and one methyldopa- 
exposed case. In trying to  tie these findings and evi- 
dence from the literature together it was hypothesized 
that the primary mechanism by which ACEIs affect 
development of the fetal kidney is through decreased 
renal blood flow (Martin et al., '92). This hypothesis 
was supported by Landing et al. ('94), who noted that 
RTD has been seen as a unilateral lesion in young in- 
fants with renal artery stenosis due to arteritis or me- 
dial arterial calcinosis and resembles the renal tubular 
atrophy of end-stage kidney diseases such as glomeru- 
lonephritis, tubulointerstitial kidney disease, obstruc- 
tive uropathy and pyelonephritis, graft rejection of 
transplanted kidneys, and the renal parenchymal 
changes associated with protracted dialysis therapy. 
Landing et al. ('94) reported that labeled lectins that 
differentially mark proximal convoluted, distal convo- 
luted, connecting, and collecting tubules in RTD 
showed no distinctive differences in the staining pat- 
terns of their hypoplastic renal tubules compared with 
those associated with postnatal renal artery obstruc- 
tion or various types of end-stage renal disease. These 
findings suggest that the renal tubular changes seen in 
some if not all the conditions cited, including RTD, are 
the result of renal ischemia. 
RTD, with hypoplasia especially of renal proximal 
convoluted tubules and clinical neonatal anuria or olig- 
uria, has also been reported as a congenital familial 
(autosomal recessive) disease, variably with features of 
oligohydramniotic deformation and pulmonary hy- 
poplasia (reviewed by Allanson et al., '92). According to 
Landing et al. ('94), the microscopic appearance of the 
kidneys in hereditary RTD is indistinguishable from 
that seen in cases of renal ischemia. It must also be 
noted that RTD has been reported in association with 
exposure to nonsteroidal anti-inflammatory agents, 
particularly indomethacin (Simeoni et al., '89; Res- 
taino et al., '91; Bavoux, '92; Buderus et al., '93; Voyer 
et al., '94). Thus it would seem that RTD is not specific 
for ACEI exposure, but rather that ACEIs are rather 
proficient at creating the conditions that lead to RTD. 
Hypocalvaria 
Apart from the renal failure and related abnormali- 
ties discussed above, six ACEI-exposed cases have had 
hypoplasia of the membranous bones of the skull, or 
hypocalvaria (Duminy and Burger, '81; Rothberg and 
Lorenz, '84; Mehta and Moda, '89; Pryde et al., '93). In 
this condition, the calvarial bones are found to be nor- 
mal in position and shape, but greatly reduced in size 
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Fig. 2. RTD in four different cases o f  ACEI fetopathy; note particularly the ductular ectasia, dilation 
of Bowman's spaces, and poor to  no differentiation of proximal convoluted tubules. x 20. 
(Fig. 3). The sutures and fontanels are symmetrically 
enlarged, and in severe cases, the normally developing 
brain is essentially unprotected by skull and liable to 
trauma during labor and delivery. Although there are 
now only a total of six cases in which this skull lesion 
is specifically described, I believe it is more common 
but unrecognized; it seems that many cases may be 
classified as enlarged fontanels with widely split su- 
tures, but in instances in which hydrocephaly or mac- 
roencephaly are not present. Lacking age-specific mor- 
phometrics for the size of the calvarial bones, the 
distinction of hypocalvaria in milder cases is admit- 
tedly a subjective assessment. 
The cause of the hypoplastic calvaria found with 
ACEI exposure is unknown. Endochondral bone and 
membranous bone grow and develop in entirely differ- 
ent ways. Long bones develop in a low oxygen environ- 
ment since nutrition takes place by diffusion through 
the cartilaginous epiphyses. Membranous bones, on the 
other hand, have a high degree of vascularity, and a 
high oxygen tension is required for their growth. The 
presumed fetal hypotension produced by ACEI expo- 
sure may result in hypoxic effects and thus a hypoplas- 
tic calvaria (Barr and Cohen, '91). A more remote pos- 
sibility is that inhibition of angiotensin I1 may 
concomitantly inhibit one of the variety of growth fac- 
tors involved in calvarial bone development. 
Intrauterine growth restriction 
The status of the fetal RAS in pregnancies compli- 
cated by severe intrauterine growth restriction, and its 
possible relationship to elevated fetoplacental vascular 
resistance, was explored by Kingdom et al. ('93). In an  
intrauterine growth restriction group, cord venous an- 
giotensin I1 was markedly elevated compared with con- 
trols, but angiotensin receptor concentration was not 
significantly altered, and no changes in angiotensin 
receptor affinity were observed. This suggests that 
there is augmentation of'the fetal RAS in a t  least some 
forms of intrauterine growth restriction and that re- 
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Fig. 3. Hypocalvaria. In this severe example, the fibrous tissue 
comprising the fontanels and sutures has been removed, leaving only 
the calvarial bone, to demonstrate the diminutive size of the bones. 
(Reproduced from Barr and Cohen, '91, with permission of Wiley- 
Liss.) 
sponsiveness of the fetoplacental vasculature to an- 
giotensin I1 is not diminished as might be expected 
from the elevated plasma angiotensin I1 levels. An- 
giotensin I1 may contribute to the increased fetoplacen- 
tal vascular resistance observed in this disorder. 
Intrauterine growth restriction (birth weight centile 
<lo%) has been observed in 21 of 27 cases of ACEI 
fetopathy for which birth weight information was 
given (Pryde et al., '93). In a single case (Pryde et al., 
'93: #l), limb lengths were disproportionately short by 
measurement, although not to the degree that a diag- 
nosis of short-limbed dwarfism would be made. No data 
on limb lengths are given for other cases. From mea- 
surement of limb lengths in other fetuses with pre- 
sumed hypotension, it is hypothesized that relative 
growth lag of the limbs is a marker of an adaptive shift 
of circulatory pattern in the compromised fetus, with 
circulation diminished to the periphery to preserve 
central perfusion (unpublished observations). Thus it 
could be predicted that a feature of ACEI fetopathy 
would be some shortening of the limbs. 
PDA 
A final observation which appears in reviewing re- 
ports of neonatal outcomes in pregnancies exposed to 
the ACEIs is the persistence of a PDA. While this may 
be associated with the high frequency of prematurity in 
the cases reported, it is suggested that there appears 
also to be an increased need for surgical intervention. 
Out of seven PDA cases reported in association with 
ACEI exposure, three required surgical ligation 
(Boutroy et al., '84; Caraman et al., '84; Plouin and 
Tchobroutsky, '85; Kreft-Jais et al., '88). Given the pos- 
sible effect of the ACEIs on the fetal bradykinin-pros- 
taglandin system, which would be expected to increase 
prostaglandin E and prostacyclin systemically and per- 
haps locally, the possibility that prenatal ACEIs may 
inhibit ductal closure needs to be considered. Cer- 
tainly, more data are needed before any firm conclu- 
sion can be reached on this subject. 
COULD IT BE THE MATERNAL DISEASE 
ITSELF AND NOT THE DRUG? 
ACEI fetopathy infants have been born to mothers 
whose hypertension was of widely varying etiology, in- 
cluding lupus erythematosus, renovascular hyperten- 
sion, nephrotic syndrome, glomerulonephritis, renal 
transplantation, preeclampsia, and essential hyperten- 
sion (Pryde et al., '93). Oligohydramnios, intrauterine 
growth restriction, and fetal distress are not uncom- 
mon complications of hypertensive pregnancies. How- 
ever, as discussed above, there is evidence that indi- 
cates the oligohydramnios, hypotension, and anuria of 
ACEI fetopathy are truly drug-related rather than sim- 
ply phenomena of the underlying maternal disease pro- 
cess. The evolution of oligohydramnios followed by the 
delivery of a neonate with prolonged hypotension and 
anuria has not been included in the well-described list 
of complications of maternal hypertension and its tra- 
ditional therapy, although one case of RTD has been 
observed under these circumstances (Martin et al., '92). 
With ACEI exposure, the probability is high that the 
oligohydramnios is in fact due to  a drug-related fetal 
hypotension and renal failure that persists into the neo- 
natal period. Evidence in support of this hypothesis is 
the occurrence of profound hypotension and anuria in 
some neonates given low doses of ACEIs for treatment 
of hypertension (Tack and Perlman, '88; Perlman and 
Volpe, '89; Scott and Purohit, '89; Wells et al., '90). 
Further, when ACE activity was measured in ACEI- 
exposed hypotensive neonates it was found to be pro- 
foundly blunted and appeared to  normalize only after 
dialysis removed the otherwise renally excreted drug 
(Schubiger et al., '88; Pryde et al., '93). There are reports 
that the onset of oligohydramnios was temporally re- 
lated to the initiation of ACEI therapy (Guignard et al ., 
'81; Schubiger et al., '88), and in one case the amniotic 
fluid volume increased toward normal after the ACEI 
was discontinued (Broughton-Pipkin et al., '89). 
SUMMARY 
Occasionally there is a drug whose record in preg- 
nancy is so frequently associated with adverse outcome 
of so specific a pattern that it becomes clear that its use 
must be restricted before scientific proof from epidemi- 
ological studies is obtained. I believe this to be the case 
with the drug class of ACEIs. There are mammalian 
models suggesting substantial fetotoxicity in a dose- 
related fashion. There is a strong and consistent pat- 
tern to the reported cases of ACEI-related adverse 
outcomes: the syndrome of oligohydramnios-anuria, 
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neonatal hypotension, renal dysplasia, and hypocalva- 
ria is too specific in association with the use of these 
drugs to be ignored. There is a very plausible biologic 
mechanism to explain the relationship. The features of 
ACEI fetopathy suggest that the underlying pathoge- 
netic mechanism is fetal hypotension, which may also 
result from other exposures. Thus, while the fetopathy 
may not be truly specific to ACEIs, they are particu- 
larly liable to produce adverse fetal renal effects with 
their sequels (anuria-oligohydramnios, pulmonary hy- 
poplasia, growth restriction) and hypocalvaria. 
RECOMMENDATIONS 
It is advised that ACEIs not be prescribed to  preg- 
nant women. Based on current information, exposure 
to ACEIs in the first trimester should not be considered 
an  indication for terminating a pregnancy. In such 
cases, an alternative antihypertensive regimen should 
be substituted for the drug prior to entering the second 
trimester. If a woman is inadvertently on ACEI ther- 
apy in the second or third trimesters of pregnancy, she 
should be monitored for signs of fetal toxicity, includ- 
ing oligohydramnios, growth restriction, or fetal dis- 
tress. Although oligohydramnios has been observed t o  
reverse when the ACEI is discontinued, a cautionary 
note must be sounded. The signs of fetal toxicity may 
not be detected until after irreversible damage to the 
fetus has occurred. 
In the case of an ACEI-exposed fetus, a t  the time of 
delivery or before, the pediatricians should be notified 
of the potential for neonatal hypotension and anuria 
and the possible need to attempt early dialysis to  re- 
move the otherwise renally excreted drug. However, 
the combination of hypotension and anuria makes both 
peritoneal and hemodialysis extremely difficult, and 
the mortality rate is exceptionally high. Because the 
damage that can occur from these drugs is so severe, it 
is urged that their prescription to women of childbear- 
ing potential be limited and, if they must be used, that 
the women be warned about risks to the fetus and be 
monitored very closely for the occurrence of pregnancy. 
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